Fexofenadine

What it is

Fexofenadine is a man-made antihistamine tablet or liquid, sold over the counter in the United States as Allegra and as many store-brand products. Chemically it is the acid metabolite of the withdrawn antihistamine terfenadine, which is why it carries terfenadine's antihistamine action without terfenadine's effect on the heart. Over-the-counter products list fexofenadine HCl 60 mg and 180 mg tablets, and the Drug Facts panel gives its purpose as one word: antihistamine.

What the research says

The evidence that fexofenadine relieves hay fever symptoms is solid: a meta-analysis of eight placebo-controlled trials in over 3,500 people found a significant reduction in total symptom scores with no excess of side effects. It also reduces itching and weals in chronic idiopathic urticaria. Its distinguishing feature is what it does not do: it does not enter the brain, did not impair actual car driving in a controlled study, and has no measurable effect on the heart's QT interval even at ten times the effective dose. Used as an add-on for eczema itch, the Cochrane evidence is weak and the benefit may not matter clinically. Its two notable interactions are with fruit juices, which cut its absorption by more than half, and with aluminium and magnesium antacids.

Evidence grade: Well established.

How it works

Drug class: Second-generation (non-sedating) peripherally selective H1-antihistamine; the acid metabolite of terfenadine

Fexofenadine blocks the histamine H1 receptor, the switch histamine uses to produce itching, sneezing, a running nose and weals. It is highly selective for that receptor and, unlike the older antihistamines, it does not get into the brain in any meaningful amount, which is why it does not normally cause drowsiness or slow reaction times. The wording behind this is the opening statement of a Sanofi-funded review, so it is the manufacturer-funded account of the mechanism rather than an independent appraisal. (Source 1)

What it is used for

• A meta-analysis of eight double-blind placebo-controlled trials found a significant reduction in daily reflective total symptom scores (SMD -0.42, 95% CI -0.49 to -0.35, p < 0.00001) in 1,833 people on fexofenadine against 1,699 on placebo, with no significant difference in adverse events. The reviewers rated the mean quality of the included trials as medium. Evidence: established. (Source 2)
• In a 4-week multicentre trial in 439 people with moderate to severe pruritus and urticaria, all four fexofenadine doses beat placebo on mean pruritus score, mean number of weals and total symptom score, and reduced interference with sleep and daily activities. The over-the-counter label is explicit that it does not prevent hives. Evidence: established. (Source 3)
• A Cochrane review found that fexofenadine 120 mg/d probably produces a small reduction in self-rated itch (mean difference -0.25 on a 0 to 8 scale, 95% CI -0.43 to -0.07, n = 400) but states the reduction may not be clinically meaningful, and the reviewers did not find consistent evidence that oral H1 antihistamines work as add-on therapy for eczema. Evidence: limited. (Source 4)

Interactions

• Fruit juices: grapefruit, orange and apple juice (pharmacokinetic study): Fruit juices block the intestinal transporter (OATP) that carries fexofenadine into the bloodstream, so less of the drug is absorbed. In 10 healthy people, grapefruit, orange and apple juice cut the amount reaching the blood to 30-40% of the water value. This makes the drug work less well; it is the opposite of the grapefruit effect on most drugs. The over-the-counter label simply says not to take it with fruit juices. (Source 5)
• Fruit juices (label instruction) (label): The Drug Facts panel carries the interaction as a direct instruction alongside the antacid one. (Source 6)
• Aluminium and magnesium antacids (label): Taken at the same time, aluminium- or magnesium-containing antacids reduce how much fexofenadine is absorbed. Both the allergy and the hives labels instruct users not to take them together. (Source 7)
• Alcohol (clinical trial): Fexofenadine did not add to alcohol's effect on driving. In a controlled study with a moderate alcohol challenge, the 240 mg/day regimens reduced the impairment alcohol caused. Nothing in the sources read describes alcohol raising fexofenadine levels or worsening its side effects. The same study found the first single doses impaired one laboratory tracking task, which its own conclusion does not mention. Limit: The source disagrees with itself and the quote is faithful to it. This results passage says the first single doses of 120 mg and 240 mg had significantly impairing effects on the critical tracking test, while the same abstract's conclusion says fexofenadine "has no effect on performance after being taken in the recommended dosage of 60 mg twice daily". Both statements are in the paper; a reader should not be shown only one of them. The dose wording is also misleading as printed: "twice daily treatment with 120 mg fexofenadine" means a 120 mg total daily dose split in two, that is 60 mg twice daily, because the methods state the regimens were daily doses of 120 or 240 mg each given in single and divided units. Read as 120 mg twice daily it would be double the dose actually given. (Source 8)
• Erythromycin and ketoconazole (clinical trial): These raise fexofenadine blood levels, but unlike its parent drug terfenadine the higher levels did not lengthen the QT interval when they were given together to steady state. (Source 9)

Stopping it

• No dependence, withdrawal syndrome or taper is described for fexofenadine in any source read. The only stopping instructions in the labelling are about when to stop and seek advice: if an allergic reaction to the product occurs, if hives symptoms do not improve after 3 days, or if hives have lasted more than 6 weeks. (Source 10)
• Because its effect is symptomatic, stopping it means symptoms can return; the hives labelling states directly that the product does not prevent hives or an allergic skin reaction from occurring, so nothing is being held in check once it is stopped. (Source 11)
• Nothing in the trials read suggests rebound. The eczema review found adverse events no different from placebo, mostly drowsiness and headache, and the rhinitis meta-analysis found no difference in reported adverse events; neither reports a discontinuation effect. (Source 2)

What goes wrong

The first single doses of fexofenadine measurably impaired one psychomotor test in the same study whose conclusion states the drug has no effect on performance. (Source 8)

• Randomized trial, Low certainty.
• Size: 24 healthy volunteers.
• Who: healthy volunteers aged 21 to 45 in a double-blind six-way crossover study.
• How long: tested 1.5 to 4 hours after the morning dose on days 1, 4 and 5.
• Result: effects in psychomotor tests were not significant except the critical tracking test, where the first single doses of 120 mg and 240 mg had significantly impairing effects; no numerical effect size is given in the abstract.
• Funding: Research Support, Non-U.S. Gov't (per the PubMed record)

Limit of this finding: The source disagrees with itself and the quote is faithful to it. This results passage says the first single doses of 120 mg and 240 mg had significantly impairing effects on the critical tracking test, while the same abstract's conclusion says fexofenadine "has no effect on performance after being taken in the recommended dosage of 60 mg twice daily". Both statements are in the paper; a reader should not be shown only one of them. The dose wording is also misleading as printed: "twice daily treatment with 120 mg fexofenadine" means a 120 mg total daily dose split in two, that is 60 mg twice daily, because the methods state the regimens were daily doses of 120 or 240 mg each given in single and divided units. Read as 120 mg twice daily it would be double the dose actually given.

Effects in psychomotor tests were not significant, with the exception of the critical tracking test in which the first single doses of fexofenadine, 120 and 240 mg, had significantly impairing effects.

Allergic reactions to fexofenadine products themselves are the harm the over-the-counter labelling singles out, both as a reason never to take it again and as a reason to seek help at once. (Source 12)

• Official position, Low certainty.
• Size: not quantified on the label.
• Who: over-the-counter users.
• How long: any time during use.
• Result: no rate is given; the Drug Facts panel instructs users not to use the product if they have ever had an allergic reaction to it or its ingredients.
• Funding: label held by Chattem, Inc. (Allegra Allergy SPL, effective 2026-04-14)

Limit of this finding: The quoted line is the whole of the "Do not use" section of the Drug Facts panel and is a sentence fragment: it only reads correctly directly beneath that heading, and shown on its own it inverts into an instruction to take the product. It also gives no rate - the panel never says how often allergic reactions to the product occur.

if you have ever had an allergic reaction to this product or any of its ingredients.

People with kidney disease are told to check with a doctor because the dose may need to differ, since the drug is cleared partly by the kidney. (Source 13)

• Official position, Low certainty.
• Size: not quantified on the label.
• Who: over-the-counter users with kidney disease.
• How long: any time during use.
• Result: no rate given; the panel directs users with kidney disease to a doctor to determine whether a different dose is needed.
• Funding: label held by Chattem, Inc.

Limit of this finding: The quoted line is the whole of the "Ask a doctor before use if you have" section of the Drug Facts panel and is a sentence fragment that only reads correctly directly beneath that heading. No rate or degree of kidney impairment is given, and the panel sets no dose for people with kidney disease - it refers them to a doctor.

kidney disease. Your doctor should determine if you need a different dose.

The same panel tells people with kidney disease, with hives that are an unusual colour or look bruised or blistered, or with hives that do not itch, to see a doctor before using it. (Source 14)

• Official position, Low certainty.
• Size: not quantified on the label.
• Who: over-the-counter users treating hives.
• How long: before and during use.
• Result: no rate is given; the panel directs users with kidney disease to a doctor to determine whether a different dose is needed, and treats unusually coloured, bruised or blistered hives and hives that do not itch as reasons to seek advice before use.
• Funding: label held by Chattem, Inc. (Allegra Hives 24HR SPL)

Limit of this finding: These are warning signs that the problem may not be ordinary hives, not a list of side effects of the drug. The passage prints under the panel's single "Warnings" heading together with the severe-allergy warning and the "Do not use" list, and is a set of fragments that only read correctly beneath the "Ask a doctor before use if you have" heading.

■ kidney disease. Your doctor should determine if you need a different dose. ■ hives that are an unusual color, look bruised or blistered ■ hives that do not itch

What the evidence supports

Fexofenadine reduces total symptom scores in allergic rhinitis compared with placebo, with no excess of adverse events. (Source 2)

• Meta-analysis, Moderate certainty.
• Size: 1,833 patients receiving fexofenadine (1,699 placebo) across eight trials.
• Who: mostly mixed adult and paediatric populations with allergic rhinitis; one trial children only, one adults only.
• How long: as reported in the eight included double-blind placebo-controlled trials.
• Result: daily reflective total symptom scores SMD –0.42; 95% CI –0.49 to –0.35, p < 0.00001. Adverse events OR = 1.03; 95% CI 0.87–1.22, p = 0.75. Very low heterogeneity; mean quality of included trials medium.
• Funding: Research Support, Non-U.S. Gov't (per the PubMed record); funding source not stated in the abstract.

Limit of this finding: The review's own grading of its paediatric evidence is weak: moderate quality from a single study and low quality, mainly because the populations were not specifically children, from the rest. This pooled result should not be used to say anything specific about children. The review also describes its eight included trials as seven in mixed adult and child populations, one in children only and one in adults only, which is nine trials for eight included - an inconsistency in the paper itself.

In 1,833 patients receiving fexofenadine (1,699 placebo), a significant reduction of the daily reflective total symptom scores (TSS) (SMD –0.42; 95% CI –0.49 to –0.35, p < 0.00001) was found. Positive results were also found for morning instantaneous TSS and individual nasal symptom scores (sneezing, rhinorrhea, itching, and congestion). The safety analysis did not show a significant difference in reported adverse events (AE) between the active and placebo treatment groups (OR = 1.03; 95% CI 0.87–1.22, p = 0.75). A very low heterogeneity between the studies was detected, so a fixed-effects model was used. The mean quality level of the included trials was medium. Specific information for a pediatric population may be assumed with a moderate quality of evidence from only 1 study and with a low quality of evidence, mainly due to indirectness, from the others.

All four fexofenadine doses tested beat placebo on itching, weal count and total symptom score in chronic idiopathic urticaria. (Source 3)

• Randomized trial, Moderate certainty.
• Size: 439 patients.
• Who: adults with chronic idiopathic urticaria and moderate to severe pruritus and urticaria, multicentre.
• How long: 4 weeks.
• Result: all 4 doses statistically superior to placebo (P <= .0238) for mean pruritus score, mean number of weals and mean total symptom score; less interference with sleep and daily activities (P <= .0001). Results similar for 60, 120 and 240 mg twice a day and better than the 20 mg group.
• Funding: Research Support, Non-U.S. Gov't (per the PubMed record); the trial tested the manufacturer's dose range.

Limit of this finding: All four doses in this trial were given twice a day, so "60 mg" here means 60 mg twice daily; the abstract passage does not say so, and the milligram figures are ambiguous read alone. The trial gives no adverse-event rates, only the statement that events were mild and similar across groups, so no harm rate can be taken from it. The p-values appear in the plain-text abstract as "P </=.0238" and "P </=.0001", which is NCBI's ASCII rendering of "less than or equal to". This is a single 1999 trial and its dose comparisons are not current dosing instructions.

All 4 doses of fexofenadine were statistically superior to placebo (P </=.0238) for MPS, MNW score, and MTSS. Patients receiving fexofenadine HCl also experienced significantly less interference with sleep and daily activities than patients receiving placebo (P </=.0001). Efficacy results were similar in the 60-, 120-, and 240-mg groups and were quantitatively better than those in the 20-mg group.

Over five days of dosing, fexofenadine did not impair actual car driving and did not add to alcohol's effect on driving, but the same study found the first single doses impaired one laboratory tracking task - a contradiction the paper itself does not resolve. (Source 8)

• Randomized trial, Moderate certainty.
• Size: 24 healthy volunteers (12 men, 12 women, aged 21 to 45)
• Who: healthy volunteers in a double-blind six-way crossover study, compared with clemastine 2 mg twice daily and placebo.
• How long: 5 days per treatment series, with a moderate alcohol challenge on day 5.
• Result: driving performance was consistently better on a 120 mg daily dose split twice daily (60 mg twice daily) than on placebo, significantly so on day 4; both 240 mg/day regimens significantly attenuated alcohol's adverse effect on driving on day 5; the first single doses of 120 and 240 mg significantly impaired the critical tracking test. No numerical effect sizes are given in the abstract.
• Funding: Research Support, Non-U.S. Gov't (per the PubMed record)

Limit of this finding: The source disagrees with itself and the quote is faithful to it. This results passage says the first single doses of 120 mg and 240 mg had significantly impairing effects on the critical tracking test, while the same abstract's conclusion says fexofenadine "has no effect on performance after being taken in the recommended dosage of 60 mg twice daily". Both statements are in the paper; a reader should not be shown only one of them. The dose wording is also misleading as printed: "twice daily treatment with 120 mg fexofenadine" means a 120 mg total daily dose split in two, that is 60 mg twice daily, because the methods state the regimens were daily doses of 120 or 240 mg each given in single and divided units. Read as 120 mg twice daily it would be double the dose actually given.

Fexofenadine did not impair driving performance. On the contrary, driving performance was consistently better during twice daily treatment with 120 mg fexofenadine than during treatment with placebo, significantly so on day 4. Both of the 240 mg/day regimens significantly attenuated alcohol's adverse effect on driving on day 5.

Brain imaging and pooled impairment data support fexofenadine having no measurable occupancy of brain H1 receptors and no psychomotor impairment at or above usual doses. (Source 15)

• Systematic review, Low certainty.
• Size: number of included studies not stated in the abstract.
• Who: healthy subjects and patients with allergic rhinitis or urticaria, adults and children.
• How long: varies by included study.
• Result: positron emission tomography showed no brain H1-receptor occupancy by fexofenadine; most studies gave a proportional impairment ratio of 0.
• Funding: industry-funded: Europe PMC records the funder as Sanofi, the originator of fexofenadine, and one co-author (Murrieta-Aguttes M) gives a Sanofi affiliation.

Limit of this finding: This review was funded by Sanofi, which originated fexofenadine, and one of its authors is a Sanofi employee; it states its own aim as "to reinforce the non-sedative property of fexofenadine". It searched a single database (Embase), reports no risk-of-bias assessment, and gives no occupancy percentages, study counts or doses, so nothing numeric here can be checked. "No brain H1-receptor occupancy" is the review's absolute phrasing of PET results and means none was detectable, not that brain penetration is proven to be zero; "higher than recommended doses" is not quantified anywhere in the abstract and must not be paired with any milligram figure.

Results of brain H1-receptor occupancy (H1RO) obtained from PET showed no H1RO by fexofenadine, the receptor which is known to cause sedation of H1 antihistamines. Most studies calculating PIR value as 0 showed fexofenadine to be a non-impairing oral antihistamine regardless of dose.

What the evidence does not support

As an add-on to topical treatment for eczema, the itch benefit was small and the Cochrane reviewers judged it may not be clinically meaningful. (Source 4)

• Systematic review, Moderate certainty.
• Size: one study, n = 400 for the pruritus outcome and n = 411 for adverse events, within a review of 25 studies and 3,285 participants.
• Who: adults with eczema, already on topical treatment, in secondary care settings.
• How long: one week for the fexofenadine comparison.
• Result: patient-assessed pruritus on a 0 to 8 scale: mean difference -0.25, 95% CI -0.43 to -0.07, n = 400; adverse events RR 1.05, 95% CI 0.74 to 1.50, n = 411. Evidence graded moderate quality.
• Funding: Cochrane review; funding not stated in the abstract.

Compared with placebo, fexofenadine 120 mg/d taken in adults over one week (one study) probably leads to a small reduction in patient-assessed symptoms of pruritus on a scale of 0 to 8 (mean difference (MD) -0.25, 95% CI -0.43 to -0.07; n = 400) and a greater reduction in the ratio of physician-assessed pruritus area to whole body surface area (P = 0.007; no further numerical data given); however, these reductions may not be clinically meaningful.

The Cochrane reviewers did not find consistent evidence that oral H1 antihistamines, fexofenadine among them, work as add-on therapy for eczema. (Source 16)

• Systematic review, Low certainty.
• Size: 25 studies, 3,285 randomised participants, 13 different H1 antihistamine treatments.
• Who: adults (17 studies, 1,344 people) and children (8 studies, 1,941 people) with eczema.
• How long: three days to 18 months across the review.
• Result: no pooling was possible because of diversity; the reviewers report the evidence for the main comparisons as low and moderate quality and note fexofenadine probably gives only a small improvement in self-assessed itch.
• Funding: Cochrane review; funding not stated in the abstract.

Based on the main comparisons, we did not find consistent evidence that H1 AH treatments are effective as 'add-on' therapy for eczema when compared to placebo; evidence for this comparison was of low and moderate quality. However, fexofenadine probably leads to a small improvement in patient-assessed pruritus, with probably no significant difference in the amount of treatment used to prevent eczema flares.

Fexofenadine had no significant effect on the QT interval even at more than ten times the effective dose, and no case of torsades de pointes was seen in controlled trials. (Source 9)

• Expert review, not systematic, Moderate certainty.
• Size: clinical trials in 1,160 patients with seasonal allergic rhinitis, and controlled trials with approximately 6,000 persons.
• Who: healthy volunteers and patients with seasonal allergic rhinitis.
• How long: 28 days up to 12 months across the studies summarised.
• Result: no dose-related QTc increases at up to 800 mg once daily or 690 mg twice daily for 28 days; no significant QTc increase versus placebo over 3, 6 or 12 months; no QTc increase when combined with erythromycin or ketoconazole; no case of fexofenadine-associated torsades de pointes in about 6,000 people.
• Funding: Research Support, Non-U.S. Gov't (per the PubMed record); the review summarises the sponsor's clinical database.

Fexofenadine HCl doses up to 800 mg once daily or 690 mg twice daily for 28 days resulted in no dose-related increases in QTc. Longer term studies indicated no statistically significant QTc increases compared with placebo in patients receiving fexofenadine HCl 80 mg twice daily for 3 months, 60 mg twice daily for 6 months, or 240 mg once daily for 12 months. Interaction studies showed no significant increases in QTc when fexofenadine HCl 120 mg twice daily was administered in combination with erythromycin (500 mg 3 times daily) or ketoconazole (400 mg once daily) after dosing to steady state (6.5 days). Clinical trials in patients with SAR (n = 1,160) treated with 40, 60, 120, or 240 mg twice-daily fexofenadine HCl or placebo indicated no dose-related increases in QTc and no statistically significant increases in mean QTc compared with placebo. In controlled trials with approximately 6,000 persons, no case of fexofenadine-associated torsades de pointes was observed.

The hives product's own panel says it must not be used to try to prevent hives from a known cause, because it will not stop hives occurring, and must not be used by anyone who has ever reacted to it. (Source 17)

• Official position, Low certainty.
• Size: not quantified on the label.
• Who: over-the-counter users treating hives.
• How long: any time during use.
• Result: no rate is given; the panel states the product will not stop hives from occurring and that avoiding the cause is the only way to prevent them, and directs anyone who does not know the cause of their hives to a doctor for a medical exam.
• Funding: label held by Chattem, Inc. (Allegra Hives 24HR SPL)

Limit of this finding: This is one of three sections that print under the single heading "Warnings" on the printed panel, alongside the severe-allergy warning and the "Ask a doctor before use if you have" list. None of the three is the complete warnings on its own. The passage is a list of fragments that only read correctly beneath the "Do not use" heading.

■ to prevent hives from any known cause such as: ■ foods ■ insect stings ■ medicines ■ latex or rubber gloves because this product will not stop hives from occurring. Avoiding the cause of your hives is the only way to prevent them. Hives can sometimes be serious. If you do not know the cause of your hives, see your doctor for a medical exam. Your doctor may be able to help you find a cause.

Where the evidence is mixed

Side effects reported in the fexofenadine eczema trial were mostly drowsiness and headache, at a rate no different from placebo. (Source 4)

• Systematic review, Moderate certainty.
• Size: n = 411 for the adverse-event comparison.
• Who: adults with eczema on topical treatment.
• How long: one week.
• Result: adverse events (mostly somnolence and headache) RR 1.05, 95% CI 0.74 to 1.50.
• Funding: Cochrane review; funding not stated in the abstract.

Results suggest probably little or no difference in adverse events (mostly somnolence and headache) (RR 1.05, 95% CI 0.74 to 1.50; n = 411) nor in the amount of 0.1% hydrocortisone butyrate used (co-intervention in both groups) as an indicator of eczema flare, but no numerical data were given. Evidence for this comparison was of moderate quality.

Where the research disagrees

Whether fexofenadine is worth adding to topical treatment for eczema itch

• Matterne and the Cochrane Skin review authors, Cochrane systematic review of 25 studies, 3,285 participants; no pooling possible: Based on the main comparisons, we did not find consistent evidence that H1 AH treatments are effective as 'add-on' therapy for eczema when compared to placebo; evidence for this comparison was of low and moderate quality. However, fexofenadine probably leads to a small improvement in patient-assessed pruritus, with probably no significant difference in the amount of treatment used to prevent eczema flares. Cetirizine was no better than placebo in terms of physician-assessed clinical signs nor patient-assessed symptoms, and we found no evidence that loratadine was more beneficial than placebo, although all interventions seem safe. (Source 16)
• The same review's fexofenadine-specific result, one randomised trial in 400 adults within the review, graded moderate quality: Compared with placebo, fexofenadine 120 mg/d taken in adults over one week (one study) probably leads to a small reduction in patient-assessed symptoms of pruritus on a scale of 0 to 8 (mean difference (MD) -0.25, 95% CI -0.43 to -0.07; n = 400) and a greater reduction in the ratio of physician-assessed pruritus area to whole body surface area (P = 0.007; no further numerical data given); however, these reductions may not be clinically meaningful. Results suggest probably little or no difference in adverse events (mostly somnolence and headache) (RR 1.05, 95% CI 0.74 to 1.50; n = 411) nor in the amount of 0.1% hydrocortisone butyrate used (co-intervention in both groups) as an indicator of eczema flare, but no numerical data were given. Evidence for this comparison was of moderate quality. (Source 4)

How firm the evidence is that fexofenadine never impairs performance

• Ansotegui and colleagues (systematic review), single-database systematic review with no risk-of-bias assessment reported, framed as reinforcing the non-sedative property: Clinical trials in adults and children showed fexofenadine to be well tolerated without sedative effect or impairment of cognitive/psychomotor function even at higher than recommended doses. (Source 15)
• Vermeeren and O'Hanlon (driving study), double-blind six-way crossover study in 24 healthy volunteers with a standardised on-road driving test: Effects in psychomotor tests were not significant, with the exception of the critical tracking test in which the first single doses of fexofenadine, 120 and 240 mg, had significantly impairing effects. (Source 8)
• Vermeeren and O'Hanlon's own conclusion, in the same abstract, the conclusion of the same double-blind six-way crossover study in 24 healthy volunteers whose results section reports significant impairment on the critical tracking test at the first single 120 mg and 240 mg doses: It was concluded that fexofenadine has no effect on performance after being taken in the recommended dosage of 60 mg twice daily. (Source 18)

How much

• Reference intake: There is no reference intake: fexofenadine is a medicine, not a nutrient. As a regulatory position, the Allegra Allergy Drug Facts panel (Chattem, Inc., effective 2026-04-14) gives the 24-hour product's directions for adults and children 12 and over, says not to use it in children under 12, and tells people over 65 and people with kidney disease to ask a doctor. (Source 19)
• Upper limit: No tolerable upper intake exists. The label's ceiling is the instruction in the same panel not to exceed one 180 mg tablet in 24 hours, alongside the active-ingredient statement that the two marketed strengths are 60 mg and 180 mg. (Source 20)
• Studied: The chronic idiopathic urticaria trial gave 20, 60, 120 or 240 mg twice a day or placebo for 4 weeks in 439 people. (Source 21)
• Studied: The driving study gave daily totals of 120 or 240 mg, each as single and divided units, over 5 days, against clemastine 2 mg twice daily and placebo. (Source 22)
• Studied: Cardiac safety studies went up to 800 mg once daily or 690 mg twice daily for 28 days in healthy volunteers, and 240 mg once daily for 12 months in patients. (Source 9)
• Studied: The fruit-juice interaction study gave a single 120 mg dose with water or with 1.2 L of juice over 3 hours in 10 healthy subjects. (Source 23)

A common belief, and what the research shows

The belief: Grapefruit juice makes drugs stronger, so it must make fexofenadine stronger too.

What the research shows: The opposite. For most drugs grapefruit blocks the CYP3A enzyme and raises blood levels; for fexofenadine the dominant effect is blocking the intestinal uptake transporter, so less gets in. In 10 healthy subjects, "Grapefruit, orange, and apple juices decreased the fexofenadine area under the plasma concentration-time curve (AUC), the peak plasma drug concentration (C(max)), and the urinary excretion values to 30% to 40% of those with water". Orange and apple juice did the same. The label's instruction is simply "do not take with fruit juices (see Directions)". Taking it with juice is likely to make it work less well, not more.

Questions and answers

What is it?

Fexofenadine is a synthetic antihistamine sold over the counter as tablets and as a liquid for children. It is the acid metabolite of terfenadine, an older antihistamine withdrawn because it could disturb heart rhythm; fexofenadine keeps the antihistamine action without that effect. It is a highly selective blocker of the histamine H1 receptor and does not cross into the brain. (Source 24)

What does it do in the body?

It occupies the H1 histamine receptor on cells in the nose, eyes and skin, so histamine released during an allergic reaction cannot trigger itching, sneezing, a running nose or weals. The quoted passage is the opening framing of a Sanofi-funded review rather than one of its results: it states as a premise that fexofenadine does not cross the blood-brain barrier and so does not cause sedation, and then sets out to reinforce that property. The review's actual results, brain imaging and pooled impairment scores, are reported separately in this write-up. (Source 1)

Is it good or bad for you?

For hay fever and for hives the placebo-controlled evidence is good and side effects in trials were no commoner than with placebo. Its cardiac safety record is reassuring even at very high doses. It is less useful than people expect for eczema itch, and it does not prevent hives or anaphylaxis: the hives labelling is explicit that it is not a substitute for an adrenaline injector. The quote below is only the severe-allergy part of that panel; two further sections, "Do not use" and "Ask a doctor before use if you have", print under the same "Warnings" heading and are recorded separately in this write-up. (Source 25)

How do you get more of it?

This question does not apply in the nutrient sense: fexofenadine is a manufactured drug and no food contains it. Over-the-counter products supply it as 60 mg and 180 mg tablets and as an oral liquid. The documented way to get less of it into the blood is to take it with fruit juice or an aluminium or magnesium antacid. (Source 20)

If it is harmful, what reduces it?

Fexofenadine is not harmful in the sense this question assumes, and no procedure to remove it is described in the sources read. It is cleared by the body, mostly unchanged, which is why people with kidney disease are told to check the dose with a doctor. The labelling's only removal instruction is for overdose: get medical help or contact a Poison Control Center. (Source 13)

Why might someone be low in it or missing it?

Someone can be effectively without fexofenadine even while taking it, which is the unusual thing about this drug. Taking it with grapefruit, orange or apple juice cuts the amount reaching the blood to 30-40%, and aluminium or magnesium antacids taken at the same time reduce absorption too. Otherwise people simply stop it when the pollen season ends, or never take it because the label excludes children under 12 for the adult products. (Source 5)

Which whole foods contain it or feed it?

No whole food contains fexofenadine. Food matters here only because it interferes: grapefruit, orange and apple juice reduce its absorption by more than half, so the label instructs taking it with water rather than juice. The directions on the 24-hour product say to take the tablet with water. (Source 19)

What happens if you do not have it?

Nothing happens from a physiological point of view: there is no deficiency state, because this is a drug and not a nutrient. What returns is the symptoms it was suppressing. In the hay fever trials, people on placebo had significantly worse total symptom scores than those on fexofenadine, and in the 1999 hives trial all active doses beat placebo on itching and weals. That trial's remark that doses of 60 mg twice a day or greater were most effective is what it found in 1999 about its own twice-daily regimens; it is not a dosing instruction and it does not match today's over-the-counter labelling, which is one 180 mg tablet a day. (Source 26)

How can you test for it?

There is no clinical blood test for fexofenadine and no monitoring is required; the sources read describe blood-level measurement only inside pharmacokinetic research, where plasma concentration and urinary excretion were measured after a single dose. Allergy itself is tested by skin prick or specific IgE testing, not by measuring the drug, and antihistamines are usually stopped before skin testing - but no source we reached states that rule, so it is not asserted here. (Source 23)

We searched: DailyMed SPLs for Allegra Allergy, Allegra Hives 24HR, Children's Allegra and 21 other fexofenadine products (no therapeutic drug monitoring section in any), and PubMed via NCBI eutils for fexofenadine pharmacokinetic and safety studies; the only measurement described is research plasma and urine sampling

References

1. Current medical research and opinion. Why fexofenadine is considered as a truly non-sedating antihistamine with no brain penetration: a systematic review.. 2024. PMID 39028636, DOI 10.1080/03007995.2024.2378172. Read the source
2. International archives of allergy and immunology. Systematic review on the efficacy of fexofenadine in seasonal allergic rhinitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials.. 2011. PMID 21969990, DOI 10.1159/000321896. Read the source
3. The Journal of allergy and clinical immunology. A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria.. 1999. PMID 10550755, DOI 10.1016/s0091-6749(99)70091-6. Read the source
4. The Cochrane database of systematic reviews. Oral H1 antihistamines as 'add-on' therapy to topical treatment for eczema.. 2019. PMID 30666626, DOI 10.1002/14651858.CD012167.pub2. Read the source
5. Clinical pharmacology and therapeutics. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine.. 2002. PMID 11823753, DOI 10.1067/mcp.2002.121152. Read the source
6. Chattem, Inc. (DailyMed SPL). Allegra Allergy (fexofenadine hydrochloride) tablet, film coated - Drug Facts - When using this product. 2026. Read the source
7. Chattem, Inc. (DailyMed SPL). Allegra Hives 24HR (fexofenadine hydrochloride) tablet, film coated - Drug Facts - When using this product. 2026. Read the source
8. The Journal of allergy and clinical immunology. Fexofenadine's effects, alone and with alcohol, on actual driving and psychomotor performance.. 1998. PMID 9525444, DOI 10.1016/S0091-6749(98)70240-4. Read the source
9. The American journal of cardiology. Cardiovascular safety of fexofenadine HCl.. 1999. PMID 10335761, DOI 10.1016/s0002-9149(99)00124-1. Read the source
10. Chattem, Inc. (DailyMed SPL). Allegra Hives 24HR (fexofenadine hydrochloride) tablet, film coated - Drug Facts - Stop use and ask a doctor if. 2026. Read the source
11. Chattem, Inc. (DailyMed SPL). Allegra Hives 24HR (fexofenadine hydrochloride) tablet, film coated - Drug Facts - Uses. 2026. Read the source
12. Chattem, Inc. (DailyMed SPL). Allegra Allergy (fexofenadine hydrochloride) tablet, film coated - Drug Facts - Do not use. 2026. Read the source
13. Chattem, Inc. (DailyMed SPL). Allegra Allergy (fexofenadine hydrochloride) tablet, film coated - Drug Facts - Ask a doctor before use if you have. 2026. Read the source
14. Chattem, Inc. (DailyMed SPL). Allegra Hives 24HR (fexofenadine hydrochloride) tablet, film coated - Drug Facts - Ask a doctor before use if you have. 2026. Read the source
15. Current medical research and opinion. Why fexofenadine is considered as a truly non-sedating antihistamine with no brain penetration: a systematic review.. 2024. PMID 39028636, DOI 10.1080/03007995.2024.2378172. Read the source
16. The Cochrane database of systematic reviews. Oral H1 antihistamines as 'add-on' therapy to topical treatment for eczema.. 2019. PMID 30666626, DOI 10.1002/14651858.CD012167.pub2. Read the source
17. Chattem, Inc. (DailyMed SPL). Allegra Hives 24HR (fexofenadine hydrochloride) tablet, film coated - Drug Facts - Do not use. 2026. Read the source
18. The Journal of allergy and clinical immunology. Fexofenadine's effects, alone and with alcohol, on actual driving and psychomotor performance.. 1998. PMID 9525444, DOI 10.1016/S0091-6749(98)70240-4. Read the source
19. Chattem, Inc. (DailyMed SPL). Allegra Allergy (fexofenadine hydrochloride) tablet, film coated - Drug Facts - Allegra 24 Hour Directions. 2026. Read the source
20. Chattem, Inc. (DailyMed SPL). Allegra Allergy (fexofenadine hydrochloride) tablet, film coated - Drug Facts - Active ingredient. 2026. Read the source
21. The Journal of allergy and clinical immunology. A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria.. 1999. PMID 10550755, DOI 10.1016/s0091-6749(99)70091-6. Read the source
22. The Journal of allergy and clinical immunology. Fexofenadine's effects, alone and with alcohol, on actual driving and psychomotor performance.. 1998. PMID 9525444, DOI 10.1016/S0091-6749(98)70240-4. Read the source
23. Clinical pharmacology and therapeutics. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine.. 2002. PMID 11823753, DOI 10.1067/mcp.2002.121152. Read the source
24. The American journal of cardiology. Cardiovascular safety of fexofenadine HCl.. 1999. PMID 10335761, DOI 10.1016/s0002-9149(99)00124-1. Read the source
25. Chattem, Inc. (DailyMed SPL). Allegra Hives 24HR (fexofenadine hydrochloride) tablet, film coated - Drug Facts - Warnings. 2026. Read the source
26. The Journal of allergy and clinical immunology. A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria.. 1999. PMID 10550755, DOI 10.1016/s0091-6749(99)70091-6. Read the source